Anavex Life Sciences (AVXL) Reports Q1 Loss of $0.12/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Anavex Reports Fiscal First Quarter 2016 Financial Results
February 8, 2016 7:00 AM ESTNEW YORK, Feb. 08, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimers disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three months ended December 31, 2015.
Financial Highlights:
Anavex had cash and cash equivalents of approximately $13.8 million as of December 31, 2015, compared to approximately $15.3 million as at September 30, 2015.Anavex used approximately $1.5 million in net cash during the first three... MoreIMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Ongoing Investigation of Anavex Life Sciences Corp. and Urges Investors with Losses in Excess of $250,000 to Contact the Firm
February 5, 2016 7:01 PM ESTLOS ANGELES--(BUSINESS WIRE)-- Lundin Law PC announces it is investigating claims against Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL) concerning... More
